Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Valeo Pharma Inc VPHIF

Healthcare
Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.


GREY:VPHIF - Post by User

Valeo Pharma Inc > Management says warrants are NOT being accelerated by the co
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(24)
•••
Comment by Higherhopes2020on Aug 10, 2020 10:49am
203 Views
Post# 31387215

RE:RE:RE:RE:Management says warrants are NOT being accelerated by the co

RE:RE:RE:RE:Management says warrants are NOT being accelerated by the coNormally warrents expiring in 2 years from now will have at least a dollar premium attached to it.
vph.wt do not have any premium(conversion at 60cents). This means the warrent are trading at discount.   President and CEO of Valeo Pharma clearly indicates that he does not need any funds to improve cash flow.  This means they there are not going to accelerate the warrents conversion in the near future. The VPH.WT are cheap.

"Our summer product launches are leading to improved cash flow and we therefore will not accelerate the expiry date of the Warrants at this stage" said Steve Saviuk, President and CEO of Valeo Pharma.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities